FDA Reauthorization Act of 2017

S. 934 · 115th Congress · Apr 25, 2017 · Lineage

A BILL

To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.

Section 1 Short title

This Act may be cited as the “FDA Reauthorization Act of 2017”.

Sec. 2 Table of contents

The table of contents for this Act is as follows:

Lineage

Apr 25, 2017viewing Reported in Senate Mr. Alexander (for himself and Mrs. Murray) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions See what changed
Apr 25, 2017 Introduced in Senate Mr. Alexander (for himself and Mrs. Murray) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

FDA Reauthorization Act of 2017

Section 1 Short title

Sec. 2 Table of contents

Cite this provision

Incoming references